Group 1 - Jefferies reports that after President Trump's threat of a 200% drug tariff, he announced a 100% tariff on brand-name or patented drugs to promote domestic manufacturing [1] - The impact on Chinese pharmaceutical companies is expected to be limited due to their minimal direct sales in the U.S. market and the ability to collaborate with multinational pharmaceutical companies to avoid tariff effects [1] - For CDMO companies, it is anticipated that the increased production costs in the U.S. will be borne by multinational pharmaceutical clients [1] Group 2 - WuXi Biologics has established production capacity in the U.S., currently having 4,000 liters in New Jersey and plans to add 36,000 liters by 2027 [1] - In contrast, Samsung Biologics has not yet established a facility in the U.S., suggesting a potential investment opportunity in WuXi Biologics during stock price adjustments [1]
大行评级｜杰富瑞：美国拟对品牌药品征收100%关税 预计对中国药企影响有限